![](https://library.celltelligence.com/wp-content/uploads/2022/09/Celltelligence-Featured-Images-1.png)
$0
Servier Discontinues Partnership with Allogene
On Wednesday, September 21, Allogene reported (SEC Filing) that Servier has discontinued its involvement in the development of allogeneic CD19-directed assets, including Allogene’s most advanced candidates such as ALLO-501, ALLO-501A, and UCART19. Below, Celltelligence provides insights on how the lack of an ex-US licensing partner could affect Allogene’s pipeline development.